ArGEN-X, a Dutch biopharmaceutical company focused on the discovery and development of human monoclonal antibodies, has strengthened its supervisory board with the appointment of David Lacey.
Lacey is a former senior vice president and head of discovery research at Amgen with more than 30 years of basic and clinical research experience. He was most recently responsible for leading more than 1,200 scientists in Amgen's discovery research unit across a portfolio of discovery and preclinical projects in haematology/oncology, inflammation, metabolic disorders and neuroscience.
Since his recent retirement, Lacey remains active in the biopharmaceutical industry, advising a number of academic institutions, biotechnology companies and venture capital firms.
Tim Van Hauwermeiren, CEO of arGEN-X, said: ‘With David on board, we are in an ideal position to further our company ambition as a first-in-class antibody discovery and development enterprise.’